Functional cure in HBV: Going the distance 2024

Networking and learning resources Hep B Media
,
1

In July 2024, GSK held a symposium titled, ‘Functional cure in HBV: Going the distance 2024’ at the Singapore Hepatology Conference.
This symposium was facilitated by Prof Tatsuya Kanto, @ThomasTu , Prof Lai Wei and Dr Kosh Agarwal. All speakers gave great talks about establishing a functional cure as a valuable clinical endpoint for people living with CHB and the potential strategies that could achieve a functional cure for HBV.

Have a listen to the video of the symposium: Symposium | Functional cure in HBV: Going the distance - Singapore Hepatology Conference (shc-sg.com) and if you have any questions please post them below :grin:.

4 Likes
2

Seeing Thomas Tu name on the panelists made me to go and watch the symposium

Congratulations to professor Thomas Tu on the attainment of your professorships status
You are really an inspiration to some of us to still strive for progress in our respective career.at a point I wanted to drop my dream of becoming a nurse and to drop my My dream of migration to the USA due to CHB status but your advocacy is such an inspiration

Please my questions is can been on NUC
Reduce the risk of developing a HCC

My doctor has refused to put me on NUC due to low viral load and positive hepatitis e antibody

What can I do and what is the relationship between CHB and fatty liver disease i was just diagnosed with grade 1 fatty liver disease and it’s quite depressing

2 Likes
3

Thanks @Sent-d for the kind words. In general, yes, NUCs can reduce the risk of HCC. However, for people with low viral loads the risk of cancer is generally low, so any benefits cannot be measured without looking at large numbers of patients or following them for a long time (both options cost quite a bit of money).

Grade 1 fatty liver disease is common in the developed world (the majority of the population in many countries), but it does not necessary lead to liver damage if controlled and if it doesn’t advance. In general, I don’t think strong evidence has shown whether this amount of mild fatty liver disease affects CHB disease progression to a detectable level.

Hope this helps,
Thomas

4

Thanks so much for your efforts and reply and thanks for your advocacy for the people leaving with CHB

1 Like